Literature DB >> 11134674

Opioid receptor and peptide gene polymorphisms: potential implications for addictions.

K S LaForge1, V Yuferov, M J Kreek.   

Abstract

Addictions to drugs of abuse and alcohol have been shown by studies of genetic epidemiology to have both a heritable and an environmental basis, with these factors influencing addiction to different substances to a different extent. In the search for specific alleles of specific genes that may contribute to the development of the addictions, many researchers have focused on the endogenous opioid system, which mediates a diverse array of neurological, physiological, and behavioral functions. The endogenous opioid system is also centrally important in mediating the effects of drugs of abuse and alcohol. Polymorphisms, including single nucleotide polymorphisms, have been identified in genes of the endogenous opioid receptors and peptides. A number of recent genetic association studies and a few studies of potential function provide clues as to which genes and which alleles may have implications for human physiology and pathophysiology, including the addictions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134674     DOI: 10.1016/s0014-2999(00)00819-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  36 in total

1.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden.

Authors:  G Bart; M Heilig; K S LaForge; L Pollak; S M Leal; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

2.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

3.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 4.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

5.  Genotype patterns that contribute to increased risk for or protection from developing heroin addiction.

Authors:  D A Nielsen; F Ji; V Yuferov; A Ho; A Chen; O Levran; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2008-01-15       Impact factor: 15.992

6.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

7.  On the role of genetic testing for personalized drug overdose management.

Authors:  Alex Manini; Michelle Jacobs; David Vlahov; Yasmin Hurd
Journal:  J Med Toxicol       Date:  2013-09

Review 8.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 9.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

Review 10.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.